Work

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone

Year: 2018

Type: article

Abstract: This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2018.5457

Authors: Dickran Kazandjian, Neha Korde, Sham Mailankody, Elizabeth Hill, William D. Figg, Mark Roschewski, Ola Landgren

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Leukemia and Lymphoma Society, Celgene, Memorial Sloan-Kettering Cancer Center, Glenmark Pharmaceuticals, Yakult Honsha, National Institutes of Health, Takeda Oncology, Juno Therapeutics, National Cancer Institute

Awards: G2399075772, G289723095, Cancer Center Support Grant

OpenAlex ID: W2902123373

FWCI: 3.495

Cites: 6

Cited by: 38

Related to: 10